Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.
作者信息
Mougalian Sarah S, Kish Jonathan K, Zhang Jingchuan, Liassou Djibril, Feinberg Bruce A
机构信息
Yale Medical School, Yale Cancer Center, New Haven, CT, USA.
Cardinal Health Specialty Solutions, Dublin, OH, USA.
出版信息
Adv Ther. 2021 May;38(5):2226-2228. doi: 10.1007/s12325-021-01683-0.
Abstract
摘要
相似文献
1
Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.对《艾瑞布林治疗转移性乳腺癌的疗效：美国10年真实世界临床经验》的勘误
Adv Ther. 2021 May;38(5):2226-2228. doi: 10.1007/s12325-021-01683-0.
2
Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.厄瑞布林治疗转移性乳腺癌的疗效：美国真实世界临床经验 10 年。
Adv Ther. 2021 May;38(5):2213-2225. doi: 10.1007/s12325-020-01613-6. Epub 2021 Jan 24.
3
Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.对《艾日布林治疗转移性乳腺癌的疗效：美国10年真实世界临床经验》的勘误
Adv Ther. 2021 Jun;38(6):3487. doi: 10.1007/s12325-021-01780-0.
4
Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.真实世界中艾瑞布林治疗局部晚期或转移性乳腺癌的疗效的系统评价。
Curr Med Res Opin. 2020 Dec;36(12):2025-2036. doi: 10.1080/03007995.2020.1835853. Epub 2020 Oct 26.
5
Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.甲磺酸艾瑞布林治疗转移性三阴性乳腺癌的临床获益：美国社区肿瘤学环境中治疗患者的长期结局。
Cancer Med. 2018 Sep;7(9):4371-4378. doi: 10.1002/cam4.1705. Epub 2018 Jul 31.
6
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK).一项关于艾立布林在韩国乳腺癌患者中的有效性和安全性的全国性、多中心回顾性研究（REMARK）。
Breast. 2020 Dec;54:121-126. doi: 10.1016/j.breast.2020.09.004. Epub 2020 Sep 16.
7
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.在日本局部晚期或转移性乳腺癌患者中使用艾立布林的安全性和有效性：一项上市后观察性研究。
Invest New Drugs. 2017 Dec;35(6):791-799. doi: 10.1007/s10637-017-0486-4. Epub 2017 Jun 29.
8
Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.甲磺酸艾瑞布林（E7389）：在乳腺癌、胰腺癌、头颈部癌和非小细胞肺癌中的疗效和耐受性评价。
Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25.
9
Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.真实世界中广泛预处理转移性乳腺癌患者中的艾立布林：一项回顾性研究。
Oncology. 2018;94 Suppl 1(Suppl 1):10-15. doi: 10.1159/000489063. Epub 2018 Jul 23.
10
Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.艾日布林用于经治转移性乳腺癌患者：TROTTER试验结果——一项关于艾日布林在现实生活中的多中心回顾性研究
Springerplus. 2016 Jan 21;5:59. doi: 10.1186/s40064-016-1700-0. eCollection 2016.
Zotero 插件